EUCTR2010-022837-27-BE进行中（未招募）1 期
An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Have multicentric Castleman's disease
- •- Have previously been enrolled in Study C0328T03 or CNTO328MCD2001 (either treatment arm)
- •- Have had their last administration of study treatment (siltuximab or placebo) less than 6 weeks (window of plus 2 weeks) prior to first dose
- •- Patients must not have had disease progression while receiving siltuximab. For those patients originally assigned to placebo in the CNTO328MCD2001 study, patients who have received less than 4 months of siltuximab following crossover will also be eligible
- •- Have adequate clinical laboratory parameters within 2 weeks prior to the first dose of siltuximab for this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •- Unmanageable toxicity, an adverse event, progression of disease, or withdrawal of consent as reason for discontinuing treatment from previous sponsor-initiated siltuximab study
- •- Vaccination with live, attenuated vaccines within 4 weeks of first dose of this study
- •- Known unmanageable allergies, hypersensitivity, or intolerance to monoclonal antibodies or to murine, chimeric, or human proteins or their excipients
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's DiseaseMulticentric Castleman's DiseaseMedDRA version: 14.1 Level: PT Classification code 10050251 Term: Castleman's disease System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022837-27-GBJanssen-Cilag International N.V.60
进行中（未招募）
1 期
A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's DiseaseMulticentric Castleman's DiseaseMedDRA version: 17.0Level: PTClassification code 10050251Term: Castleman's diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022837-27-DEJanssen-Cilag International N.V.75
进行中（未招募）
1 期
A Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Patients with Multicentric Castleman's DiseaseEUCTR2010-022837-27-ESJanssen-Cilag International N.V.80
进行中（未招募）
1 期
A Study to Evaluate the Safety and Effectiveness of Intravenous CR845 in Hemodialysis Patients with Moderate-to-Severe PruritusEUCTR2018-004572-35-CZCara Therapeutics, Inc.400
进行中（未招募）
1 期
A Study to Evaluate the Safety and Effectiveness of Intravenous CR845 in Hemodialysis Patients with Moderate-to-Severe PruritusModerate-to-Severe Pruritus in Hemodialysis PatientsEUCTR2018-004572-35-PLCara Therapeutics INC400